BMS's Opdivo more than doubles 1-year survival in lung cancer
This article was originally published in Scrip
Enthusiasm for Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) grew on 30 October when the company revealed Phase II data that showed one-year survival was more than double historical results in third-line treatment of squamous cell non-small cell lung cancer (NSCLC) patients.
You may also be interested in...
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.